As we have pointed out, MYCN-amplification augments mitochondrial function and OXPHOS in neuroblastoma tumours [45,46,50], therefore targeting Aurora-A might reverse this phenomenon and expose metabolic vulnerabilities previously deemed evasive due to the so-called undruggablity of MYCN. Here, MYCN is linked to neuroblastoma.